Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250010 | 0.86 | ACHE (0.67) | ACHEMAPK1MAPTKDM4EALDH1A1 | |
| SCHEMBL15905152 | 0.85 | SLC2A1 (0.55) | ACHEMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4243803 | 0.85 | ACHE (0.49) | ACHEMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL4247635 | 0.85 | ACHE (0.49) | ACHEKDM4EALDH1A1RAB9AHPGD | |
| SCHEMBL4248494 | 0.84 | ACHE (0.49) | ACHEMAPK1MAPTKDM4EALDH1A1 | |
| SCHEMBL4852658 | 0.82 | MAPK1 (0.47) | MAPK1MAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL15919728 | 0.81 | ACHE (0.45) | ACHEKDM4EPOLBHTTRAD52 | |
| SCHEMBL4253191 | 0.81 | KDM4E (0.51) | ACHEMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL4247683 | 0.81 | TOP1 (0.46) | ACHEMAPTSMN1; SMN2LMNA | |
| SCHEMBL4247643 | 0.78 | ALDH1A1 (0.66) | MAPTKDM4EALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | claimed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | claimed |
| EP-1709045-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2006-10-11 | — | — | EP | claimed |
| US-20050171141-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-04 | — | — | US | claimed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | claimed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1709045-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050171141-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-04 | — | — | US | disclosed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171141-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | ACHE 141/4885MAPK1 2788/4885MAPT 2360/4885 |
| US-20090042928-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | ACHE 141/4885MAPK1 2788/4885MAPT 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.